Patents Assigned to Singapore Health Services Pte, Ltd
-
Publication number: 20240141004Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition or IL-11-mediated signalling.Type: ApplicationFiled: August 31, 2023Publication date: May 2, 2024Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer, Wei Wen Lim, Benjamin Wei Ming Ng
-
Patent number: 11939374Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: GrantFiled: December 2, 2020Date of Patent: March 26, 2024Assignees: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20240024419Abstract: The invention relates to methods of increasing sensitivity of an epidermal growth factor receptor (EGFR)-related cancer to EGFR tyrosine kinase inhibitor (TKI) comprising administering a therapeutically effective amount of EGFR isoform D to a subject in need thereof. The invention also relates to methods of treating a subject suffering from an EGFR-related cancer comprising administering to the subject an effective amount of EGFR isoform D and a TKI. In one embodiment, the EGFR-related cancer is head and neck squamous cell carcinoma (HNSCC).Type: ApplicationFiled: August 25, 2021Publication date: January 25, 2024Applicant: SINGAPORE HEALTH SERVICES PTE LTDInventors: Fui Teen CHONG, Dorival MENDES RODRIGUES-JUNIOR, Narayanan Gopalakrishna IYER, Hui Sun LEONG, Daniel Shao-Wen TAN, Darren Shen Yon TOH
-
Publication number: 20230399393Abstract: The present disclosure relates to the diagnosis, treatment and prophylaxis of age-related diseases, and increasing healthspan. Provided are methods of treating or preventing an age-related disease/condition, and in particular of treating or preventing frailty, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject. Also provided are agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in such a method. Further provided is the use of agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in such a method.Type: ApplicationFiled: October 29, 2021Publication date: December 14, 2023Applicants: National University of Singapore, Singapore Health Services PTE LTD.Inventors: Benjamin Corden, Anissa Widjaja, Sebastian Schaeffer, Stuart Cook, Brijesh Kumar Singh
-
Patent number: 11820821Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.Type: GrantFiled: December 22, 2021Date of Patent: November 21, 2023Assignees: SINGAPORE HEALTH SERVICES PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Hau Wan Leung, Andre Boon Hwa Choo, Mei Yee Vanessa Ding, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
-
Patent number: 11813311Abstract: Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.Type: GrantFiled: May 1, 2020Date of Patent: November 14, 2023Assignees: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer, Brijesh Kumar Singh, Anissa Widjaja
-
Patent number: 11802139Abstract: The present invention relates to compounds comprising formula I: Amino Acid Sequence-(L)n-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent L is a linker unit,—is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.Type: GrantFiled: December 10, 2021Date of Patent: October 31, 2023Assignee: SINGAPORE HEALTH SERVICES PTE. LTD.Inventor: Salvatore Albani
-
Publication number: 20230326127Abstract: Methods and systems for simulating a stent in a coronary artery lumen structure are disclosed. A method of simulating a stent in a coronary artery lumen structure, the method comprises: reconstructing a three-dimensional coronary artery tree from segmented coronary lumen contours; replacing part of the three-dimensional artery tree with a candidate stent structure; and simulating pressure distribution through the coronary artery tree to determine a non-invasive fractional flow reserve through the candidate stent structure.Type: ApplicationFiled: August 26, 2021Publication date: October 12, 2023Applicants: Singapore Health Services Pte Ltd, Agency For Science, Technology And ResearchInventors: Liang ZHONG, Weimin HUANG, Junmei ZHANG, Gaurav CHANDOLA, Soo Teik LIM, Ru San TAN, Swee Yaw TAN
-
Patent number: 11780898Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.Type: GrantFiled: October 12, 2018Date of Patent: October 10, 2023Assignees: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer, Wei Wen Lim, Benjamin Wei Ming Ng
-
Publication number: 20230285470Abstract: The invention relates to a method of generating an induced pluripotent stem cell. The method of the disclosure comprises expressing exogenous nucleic acids encoding the proteins OCT3/4, SOX2, KLF4, LIN28 and L-MYC and the p53-shRNA in a stem cell of the amniotic membrane of the umbilical cord under conditions suitable to reprogram the stem cell, thereby generating the induced pluripotent stem cell. The present invention also refer to an induced pluripotent stem cell population obtainable by the method and an induced pluripotent stem cell population obtained by the method. Further, a pharmaceutical composition comprising the induced pluripotent stem cell of the present invention is concerned. The present invention also relates to a method of differentiating the induced pluripotent stem cell of this invention. In addition, a pharmaceutical composition comprising a differentiated induced pluripotent stem cell obtained by the method is also concerned.Type: ApplicationFiled: July 15, 2021Publication date: September 14, 2023Applicants: CELLRESEARCH CORPORATION PTE LTD, SINGAPORE HEALTH SERVICES PTE LTDInventors: Chou CHAI, Kah Leong LIM, Toan Thang PHAN
-
Publication number: 20230263780Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.Type: ApplicationFiled: April 27, 2023Publication date: August 24, 2023Applicant: Singapore Health Services Pte LtdInventors: Subramanian VENKATRAMAN, Jayaganesh V. NATARAJAN, Yin Chiang Freddy BOEY, Jodhbir Singh MEHTA, Tina Tzee Ling HOWDEN, Xu Wen NG, Anthony Herr Cheun NG
-
Publication number: 20230212279Abstract: Methods of treating and preventing Alport syndrome through inhibiting interleukin 11 (EL-11)-mediated signalling are disclosed, as well as agents for use in such methods.Type: ApplicationFiled: June 17, 2021Publication date: July 6, 2023Applicants: Singapore Health Services PTE, LTD., National University of SingaporeInventors: Stuart Alexander Cook, Anissa Anindya, Sebastian Schaefer
-
Publication number: 20230213225Abstract: An isolation chamber includes a plurality of walls and ceiling defining an internal chamber and a first and second door. The doors seal engagement with the walls. A fan filter unit is arranged to extract air from the internal chamber. The isolation chamber is arranged to couple to a doorway, and the coupling arranged to provide an airtight seal about the doorway.Type: ApplicationFiled: August 31, 2020Publication date: July 6, 2023Applicants: THE BIOFACTORY PTE LTD, SINGAPORE HEALTH SERVICES PTE LTDInventors: Hairil Rizal ABDULLAH, Mavis TEO, Antonia ZENG, Zihui TAN, Gabriel TAN, Chun Siong LEE, Ron WIGHT, Marcus Hiong Tat TAN
-
Publication number: 20230201776Abstract: A graphene oxide-based membrane There is provided a graphene oxide-based membrane comprising a substrate and a plurality of layers of single-layered graphene oxide formed on the substrate, each of the plurality of layers of single-layered graphene oxide is functionalised by at least one diamine functional group, wherein interlayer spacing between two adjacent layers of single-layered graphene oxide is ? 10 Å. The membrane may be comprised in an electrocapacitive unit. There is also provided a method of forming the membrane.Type: ApplicationFiled: May 14, 2021Publication date: June 29, 2023Applicants: Singapore University of Technology And Design, Singapore Health Services Pte Ltd.Inventors: Hui Ying YANG, Zhi Yi LEONG, Debajyoti Malakar ROY, Sreekanth KODURI
-
Patent number: 11672784Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.Type: GrantFiled: April 19, 2017Date of Patent: June 13, 2023Assignees: NANYANG TECHNOLOGICAL UNIVERSITY, SINGAPORE HEALTH SERVICES PTE LTDInventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Yin Chiang Freddy Boey, Jodhbir Singh Mehta, Tina Tzee Ling Howden, Xu Wen Ng, Anthony Herr Cheun Ng
-
Patent number: 11655451Abstract: The present disclosure relates to methods for culturing human epidermal keratinocytes. When keratinocytes are cultured on plates coated with a laminin containing an alpha-4 chain or an alpha-5 chain, in a xeno-free, chemically defined cell culture medium, they expand efficiently in vitro. Useful cell culture kits for culturing keratinocytes are also described herein, as are methods of using such cells for treatment of burns or chronic wounds.Type: GrantFiled: May 4, 2018Date of Patent: May 23, 2023Assignees: NATIONAL UNIVERSITY OF SINGAPORE, SINGAPORE HEALTH SERVICES PTE LTDInventors: Karl Tryggvason, Monica Suryana Tjin, Alvin Wen Choong Chua
-
Patent number: 11647963Abstract: A method of producing an artificial neural network capable of predicting the survivability of a patient, including: storing in an electronic database patient health data comprising a plurality of sets of data, each set having at least one of a first parameter relating to heart rate variability data and a second parameter relating to vital sign data, each set further having a third parameter relating to patient survivability; providing a network of nodes interconnected to form an artificial neural network, the nodes comprising a plurality of artificial neurons, each artificial neuron having at least one input with an associated weight; and training the artificial neural network using the patient health data such that the associated weight of the at least one input of each artificial neuron is adjusted in response to respective first, second and third parameters of different sets of data from the patient health data.Type: GrantFiled: December 8, 2020Date of Patent: May 16, 2023Assignees: SINGAPORE HEALTH SERVICES PTE LTD., NANYANG TECHNOLOGICAL UNIVERSITYInventors: Marcus Eng Hock Ong, Zhiping Lin, Wee Ser, Guangbin Huang
-
Patent number: 11642350Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.Type: GrantFiled: March 22, 2018Date of Patent: May 9, 2023Assignees: Singapore Health Services PTE LTD, Santen Pharmaceutical Co., Ltd.Inventors: Tiang Hwee Donald Tan, Roger Wilmer Beuerman, Seang-Mei Saw, Aradhana Upadhyay, Masatomo Kato, Takaaki Inaba
-
Patent number: 11613568Abstract: The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using the mutant p53 polypeptide as an immunogen wherein the polypeptide comprises: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration, in particular wherein the scaffold sequence is thioredoxin. In the specific embodiments, antibodies against mutant p53 comprising R175H, R248Q or R273H are generated. Also disclosed are the uses of the antibodies for diagnosis, prognosis and stratification of patient groups and further encompasses the use of antibodies for imaging and treatment of cancer.Type: GrantFiled: October 17, 2017Date of Patent: March 28, 2023Assignees: Agency for Science, Technology and Research, Singapore Health Services Pte. Ltd., National University of SingaporeInventors: Tr Kanaga Sabapathy, David P. Lane, Le-Ann Hwang, Xin Yu Koh, Liew Oi Wah
-
Patent number: 11583612Abstract: There is provided a material comprising a multi-block thermogelling polymer, said multi-block thermogelling polymer comprising a hydrophilic polymer block; a thermosensitive polymer block; and a hydrophobic polymer block, wherein the hydrophilic polymer block, the thermosensitive polymer block and the hydrophobic polymer block are chemically coupled together by at least one of urethane/carbamate, carbonate, ester linkages or combinations thereof, and wherein the material is suitable for use as a vitreous substitute. Also provided are a method of preparing said material and a synthetic vitreous humour or part thereof comprising said material.Type: GrantFiled: February 28, 2020Date of Patent: February 21, 2023Assignees: Agency for Science, Technology and Research, National University Hospital (Singapore) Pte Ltd, National University of Singapore, Singapore Health Services Pte LtdInventors: Xian Jun Loh, Xinyi Su, Zengping Liu, Gopal Lingam, Veluchamy Amutha Barathi, Walter Hunziker